서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 21 of 21

Issue DateTitle / Author(s) / CitationFileAltmetrics
2010-10
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
DOI
2011-05
Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma Suggestion for an Effective Screening Strategy for These Tumors
DOI
2011-08
Detection of ALK gene rearrangement in non-small cell lung cancer: A comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression
DOI
2011-09
Anaplastic Lymphoma Kinase Translocation A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
DOI
2012-06
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma
DOI
2012-08
Heterogeneity of genetic changes associated with acquired crizotinib resistance in Anaplastic lymphoma kinase-rearranged lung cancer
view file
2013-01
Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases
DOI
2015-02
Prognosis prediction with immunohistochemical features and MYCN amplification in neuroblastoma
view file
2015-02
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor
DOI
2015-07
P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement
view fileDOI
2017-01
MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status
DOI
2017-02
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
DOI
2018-09
Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials
DOI
2018-10
Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibit ROS1/TRK/ALK solvent-front mutations
DOI
2020-01
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
DOI
2020-09
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC
DOI
2021-10
Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy
DOI
2022-01
Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study
DOI
2022-11
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
DOI
2023-01
Ligand-based pharmacophore modelling in search of novel anaplastic lymphoma kinase inhibitors

Gajulapalli, V. Pratap Reddy; Lee, Ju Yong; Sohn, In Suk

Results in Chemistry, Vol.5, p. 100752

DOI
2024-02
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
DOI
1